Not a good buy right now: price action is weak/indecisive (bearish MACD, RSI < 50, MAs converging) and the latest quarter showed a sharp profitability deterioration.
For an impatient buyer, the risk/reward is unattractive at 303 pre-market because upside is capped by nearby resistance (312) while downside to support (~290) is meaningful.
Hedge funds are accumulating, which is a supportive medium-term signal, but there is no confirming bullish technical or proprietary trading trigger today.
Trend/structure: Neutral-to-bearish consolidation; moving averages are converging (no strong uptrend confirmation).
Momentum: MACD histogram -1.6 (below 0) with negative momentum still in place, though contracting (selling pressure may be easing, not reversed).
RSI: RSI_6 = 42.88 (below 50), consistent with mild weakness rather than an oversold bounce setup.
Key levels vs pre-market ~303.03:
Pivot: 301.20 (price slightly above pivot; a loss of ~301 increases downside risk)
Resistance: R1 312.34 then R2 319.23 (nearby overhead supply)
Support: S1 290.06 then S2 283.17 (material downside if pivot breaks)
Quant pattern read-through: Similar-pattern stats imply slightly negative near-term skew (next day expected bias negative; month also slightly negative).
Options Data
Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning/sentiment:
Open Interest put/call at 2.26 is bearish/defensive (more puts outstanding), often consistent with hedging or cautious sentiment.
Volume put/call at 0.01 is extremely call-skewed on the day (calls traded far more than puts), which can indicate short-term speculative bullishness, but volume is small on the put side (only 1 put).
Volatility:
IV (30d) ~36.57 vs historical vol ~36.58 (roughly in-line; options not screaming mispricing).
IV percentile 42.4 / IV rank 6.48 suggests IV is not elevated versus its recent range (no strong fear premium).
Technical Summary
Sell
4
Buy
5
Positive Catalysts
Hedge funds are reported as buying aggressively over the last quarter (large increase in buying activity), which can provide support.
Selling pressure appears to be easing (MACD negative but contracting), allowing for a potential technical bounce if BIO holds above the ~301 pivot.
Next earnings event: QDEC 2025 earnings on 2026-02-17 after hours (potential catalyst if margins/profitability rebound toward expectations).
Neutral/Negative Catalysts
Options open-interest skew is defensive (high put/call OI), consistent with cautious positioning.
Financial Performance
Latest quarter: 2025/Q3
Revenue: $653.0M, +0.50% YoY (low growth).
Net income: -$341.9M, -152.34% YoY (major deterioration into a large loss).
Takeaway: Top-line is stable but profitability/margins weakened significantly, which typically suppresses near-term multiple expansion and makes breakouts harder to sustain.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target change data was provided, so the recent trend in upgrades/downgrades cannot be verified from this dataset.
How Wall Street would likely frame it based on the provided fundamentals:
Pros: sticky life-sciences tools/diagnostics franchise, modest revenue resilience, potential mean reversion if losses were driven by one-offs.
Cons: severe earnings deterioration and margin compression; without clear evidence of normalization, many analysts would stay cautious and wait for earnings proof (next catalyst: 2026-02-17).
Wall Street analysts forecast BIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIO is 357.5 USD with a low forecast of 340 USD and a high forecast of 375 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast BIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIO is 357.5 USD with a low forecast of 340 USD and a high forecast of 375 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 299.540
Low
340
Averages
357.5
High
375
Current: 299.540
Low
340
Averages
357.5
High
375
Citi
Buy
maintain
$350 -> $375
AI Analysis
2025-10-30
Reason
Citi
Price Target
$350 -> $375
AI Analysis
2025-10-30
maintain
Buy
Reason
Citi raised the firm's price target on Bio-Rad to $375 from $350 and keeps a Buy rating on the shares. The firm cites higher peer multiples for the target bump post the company's Q3 report.
Wells Fargo
Equal Weight
maintain
$265 -> $340
2025-10-30
Reason
Wells Fargo
Price Target
$265 -> $340
2025-10-30
maintain
Equal Weight
Reason
Wells Fargo raised the firm's price target on Bio-Rad to $340 from $265 and keeps an Equal Weight rating on the shares. The firm says shares of Bio-Rad should be flat on the in-line quarter and stable full year guide. Not surprisingly, Bio-Rad is cautious on 2026 growth prospects, but still expects to deliver margin expansion even on muted revenue growth, Wells adds.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BIO
